NCT05836597 Functional Dyspepsia Treatment Using Virtual Reality
| NCT ID | NCT05836597 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mayo Clinic |
| Condition | Functional Dyspepsia |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2024-04-01 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2024-04-01 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate the effectiveness of using virtual reality to treat gastrointestinal symptoms related to functional dyspepsia.
Eligibility Criteria
Inclusion Criteria: * Symptoms of dyspepsia thought to represent functional dyspepsia, meeting Rome IV criteria * Had an upper endoscopy and assessment for Helicobacter pylori; if a patient is found to have H. pylori, treatment with confirmed eradication (by stool antigen test or urea breath test) will be required before the patient is eligible for study inclusion. * Patients will be considered for the study if they have undergone a complete history and physical examination during a previously scheduled consultation/evaluation visit with a gastroenterologist in the Mayo Clinic Florida General GI or Motility clinic. Exclusion Criteria: * Symptoms are thought to represent an organic disorder (e.g., peptic ulcer disease, hepatitis, pancreatitis, inflammatory bowel disease, type I diabetes, a known malignancy, radiation-induced injury, an active infection, vasculitis, celiac disease), or patients have known uncontrolled GERD, esophagitis, eosinophilic esophagitis, or untreated H. pylori. * Patients with gastroparesis or cyclic vomiting syndrome. * Patients with prior surgery to the esophagus, stomach or duodenum. * Patients taking opioids. * Patients with motion sickness, vertigo, or a seizure disorder * IBS symptoms are not predominant.
Contact & Investigator
David Cangemi
PRINCIPAL INVESTIGATOR
Mayo Clinic
Frequently Asked Questions
Who can join the NCT05836597 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Functional Dyspepsia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05836597 currently recruiting?
Yes, NCT05836597 is actively recruiting participants. Visit ClinicalTrials.gov or contact Mayo Clinic to inquire about joining.
Where is the NCT05836597 trial being conducted?
This trial is being conducted at Jacksonville, United States.
Who is sponsoring the NCT05836597 clinical trial?
NCT05836597 is sponsored by Mayo Clinic. The principal investigator is David Cangemi at Mayo Clinic. The trial plans to enroll 30 participants.